PrIMAVeRa at the AMR Accelerator Cross-Project Meeting

Representatives from PrIMAVeRa attended the AMR Accelerator Cross-Project Meeting on 05 March, a final gathering that brought together nine European research projects working to combat antimicrobial resistance (AMR).

The meeting provided an opportunity for PrIMAVeRa to present its modelling framework, new data partnerships, major achievements to date, and next steps. With the overarching theme of sustaining the AMR Accelerator legacy beyond 2026, the team also showcased PrIMAVeRa tools designed to help stakeholders, including policymakers, funders, industry, and scientists, quantify the value of vaccines and monoclonal antibodies in reducing AMR. 

The AMR Accelerator Cross-Project Meeting brought together nine European research projects working on antimicrobial resistance for a productive final gathering. On behalf of PrIMAVeRa, we presented the modelling framework, new data partnerships, our major achievements, and next steps within the project. As the meeting theme centred on sustaining the AMR Accelerator legacy beyond 2026, we also discussed PrIMAVeRa tools that will help stakeholders (such as policymakers, funders, industry, and scientists) quantify the value of vaccines and monoclonal antibodies in reducing AMR. Pedro Miguela Villoldo, our colleague and partner from Instituto de Salud Carlos III, and I concluded it was a great opportunity to connect with the broader AMR research community and reflect on how to sustain the PrIMAVeRa legacy beyond 2026. Looking forward to continuing this work at ESCMID Global 2026, where we will be hosting a stakeholder meeting together with ecraid to align PrIMAVeRa modelling outputs with user needs. – Dr. Elske Sieswerda, University Medical Center Utrecht (PrIMAVeRa Scientific Coordinating Partner)

Sustainability was the central theme of the day, and PrIMAVeRa came away with concrete input. Highlights included the start of a brainstorm for a joint opinion paper on the AMR Accelerator’s contributions to the field, and a concrete recommendation to ensure our tools and results are accessible to AI-driven search tools, essential for future visibility. Project partners are looking forward to continued progress in combatting the proliferation of AMR within the global healthcare landscape.

This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.  www.imi.europa.eu

This communication reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.